Strategy, commercialization, and investment support for rare disease

Led by a team of seasoned biopharmaceutical executives, operators, and investors

Find out More

Initial Partnership

RareGen partnered with Sandoz to launch the first-to-file generic of Treprostinil Injection for the treatment of patients with Pulmonary Arterial Hypertension (PAH). RareGen has hired an experienced, national salesforce in PAH.
Contact Us

Management

Damian DeGoa, CEO

Damian deGoa is a Principal of the PBM Capital Group and has led several portfolio divestitures. For the past two years, he has served as CEO of Breas Medical Group, a PBM Capital portfolio company. PBM Capital sold a majority interest in Breas Medical to Fosun Pharma, a public company on the Hong Kong and Shanghai stock exchange. Damian will serve as a board member for Breas Medical Group under the new partnership.

Prior to joining PBM Capital, Damian held various roles at Perrigo Company including Head of International Business development, Divisional Finance Lead for Perrigo’s $500 million nutrition segment, and Director of Corporate Development and Rx Business Development where he concluded multiple transactions with aggregate invested capital over $1B. Damian served on the advisory board for Captek Softgels until it sold to Swander Pace Private Equity in 2016.

Damian holds a B.A. in Economics and Philosophy from the University of Michigan and a MBA in Finance from DePaul University

Scott Moomaw, COO

Scott is a seasoned leader in biopharmaceuticals. He has extensive experience launching products and developing commercial strategies and organizations. He was the Vice President of Marketing at Opko Health, launching a specialty product for Chronic Kidney Disease. He was Associate Vice President of Marketing at United Therapeutics leading a portfolio of brands to treat Pulmonary Hypertension. Scott also held a variety of sales and marketing roles of increasing responsibility at Eli Lilly for over ten years.
Scott holds his MBA from the University of Michigan and a B.S. from Miami University.

Board

Paul Manning

Paul Manning is the President and CEO of PBM Capital Group based in Charlottesville, VA. An entrepreneur with thirty years of experience in the healthcare industry, Paul founded PBM Capital Group in 2010, a private equity investment firm in the business of investing in health care and life-science related companies. Paul directs all investment decisions and sits on the Board of Directors for many of PBM Capital’s investments including: Avexis (NASDAQ:AVXS), Dova Pharmaceuticals, Verrica Pharmaceuticals, and PBM Pharmaceuticals. Paul has successfully founded several companies that developed and distributed prescription and over the counter products to major chains in the United States. In 1997, Paul founded PBM Products, which became the largest private label producer of infant formula and baby/toddler food in the world. PBM Products was sold to Perrigo Corporation in 2010. Paul served on Perrigo Corporation’s Board of Directors after the sale.

Paul is an active member of the University of Virginia community, having served on the Board of UVA Strategic Planning Committee, the Board of UVA Health Foundation, and the Board of the President’s Advisory Committee.

Paul graduated from the University of Massachusetts with a B.S. in Microbiology. Paul was named Virginia Entrepreneur of the Year by Ernst and Young in 2002.

Roger Jeffs

Roger Jeffs retired as President and co-CEO from United Therapeutics in 2016 after a successful 18 year tenure. Dr. Jeffs joined United Therapeutics Corporation during its start-up phase in 1998 as director of research, development, and medical and served as its president and chief operating officer from 2001 to 2014. While at United Therapeutics, Dr. Jeffs helped lead the IPO, oversaw the clinical development and regulatory approval of 6 products for rare diseases, and managed the commercial effort that lead to a >20% CAGR and $1.5B annual revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in “recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children”.

Dr. Jeffs previously held positions at Amgen, Inc. and Burroughs Wellcome Co where he held roles in clinical development. Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.

Dr. Jeffs served on the Board of Directors for United Therapeutics from 2001-2016, and currently serves on the Boards of four public companies: Albireo Pharma, Axsome Therapeutics, Dova Pharmaceuticals and Sangamo Therapeutics.

Damian DeGoa

Damian deGoa is a Principal of the PBM Capital Group and has led several portfolio divestitures. For the past two years, he has served as CEO of Breas Medical Group, a PBM Capital portfolio company. PBM Capital sold a majority interest in Breas Medical to Fosun Pharma, a public company on the Hong Kong and Shanghai stock exchange. Damian will serve as a board member for Breas Medical Group under the new partnership.

Prior to joining PBM Capital, Damian held various roles at Perrigo Company including Head of International Business development, Divisional Finance Lead for Perrigo’s $500 million nutrition segment, and Director of Corporate Development and Rx Business Development where he concluded multiple transactions with aggregate invested capital over $1B. Damian served on the advisory board for Captek Softgels until it sold to Swander Pace Private Equity in 2016.

Damian holds a B.A. in Economics and Philosophy from the University of Michigan and a MBA in Finance from DePaul University

Contact Us

If you have business development ideas, are looking for an investor for a commercial-ready or late stage clinical asset, or are looking for a commercial partner, please get in touch.

All Materials Copyright RareGen
Durham, NC

Back to Top